Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

272
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
272
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

163
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
163
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

161
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
161
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

249
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
249
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

198
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
198
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

159
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
159

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Central and Peripheral Neuromodulators in Functional Dyspepsia and Gastroparesis: A Symptom-Based Clinical Review.

Neurogastroenterology and motility·2026
Same author

Bloating and Distention Patients Form 6 Distinct Latent Clusters Based on Symptoms, Diet, Psychosocial, and Quality-of-Life Parameters.

The American journal of gastroenterology·2025
Same author

What elements in the physician-patient relationship (PPR) contribute to patient satisfaction: Development of a short form PPRS-Patient Version (PPRS-Patient SF) Questionnaire.

Neurogastroenterology and motility·2021
Same author

Deconstructing stigma as a barrier to treating DGBI: Lessons for clinicians.

Neurogastroenterology and motility·2021
Same author

Preliminary development and validation of the Patient-Physician Relationship Scale for physicians for disorders of gut-brain interaction.

Neurogastroenterology and motility·2020
Same author

Antidepressants in inflammatory bowel disease.

Nature reviews. Gastroenterology & hepatology·2020

Related Experiment Video

Updated: Jun 28, 2025

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.3K

Central Neuromodulators in Irritable Bowel Syndrome: Why, How, and When.

Ignacio Hanna-Jairala1, Douglas A Drossman2

  • 1Division of Gastroenterology, Department of Internal Medicine, Hospital Alcivar, Guayaquil, Ecuador.

The American Journal of Gastroenterology
|April 10, 2024
PubMed
Summary

Central neuromodulators effectively treat Irritable Bowel Syndrome (IBS) by targeting the brain-gut axis. Treatment selection and duration are key for managing IBS symptoms and preventing relapse.

More Related Videos

In vitro Functional Characterization of Mouse Colorectal Afferent Endings
14:09

In vitro Functional Characterization of Mouse Colorectal Afferent Endings

Published on: January 21, 2015

9.6K
Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

551

Related Experiment Videos

Last Updated: Jun 28, 2025

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.3K
In vitro Functional Characterization of Mouse Colorectal Afferent Endings
14:09

In vitro Functional Characterization of Mouse Colorectal Afferent Endings

Published on: January 21, 2015

9.6K
Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

551

Area of Science:

  • Neurogastroenterology
  • Pharmacology
  • Psychiatry

Background:

  • Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder often managed with central neuromodulators.
  • Central neuromodulators influence neurotransmitter systems (serotonin, noradrenaline, dopamine) along the brain-gut axis.
  • These agents impact gut motility, visceral sensitivity, and psychiatric comorbidities associated with IBS.

Purpose of the Study:

  • To review the role of central neuromodulators in Irritable Bowel Syndrome (IBS) management.
  • To guide the selection of appropriate neuromodulators based on predominant IBS symptoms and pharmacological properties.
  • To outline treatment duration, augmentation strategies, and tapering protocols for central neuromodulator therapy in IBS.

Main Methods:

  • Review of pharmacological properties of central neuromodulators used in IBS.
  • Analysis of symptom-based selection criteria for antidepressants (TCAs, SNRIs, SSRIs).
  • Discussion of treatment response timelines, relapse prevention, augmentation, and discontinuation strategies.

Main Results:

  • Tricyclic antidepressants (TCAs) are first-line for IBS pain; Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) are alternatives.
  • Selective Serotonin Reuptake Inhibitors (SSRIs) help anxiety and constipation but not pain; TCAs help diarrhea but may cause constipation.
  • Clinical response takes 6-8 weeks, with 6-12 months of treatment for relapse prevention; augmentation and slow tapering are recommended.

Conclusions:

  • Central neuromodulators are effective for IBS, with tailored selection based on symptoms (pain, anxiety, bowel habit) crucial for optimal outcomes.
  • Long-term treatment and potential augmentation with atypical antipsychotics or behavioral therapies are important for sustained IBS symptom control.
  • Careful, slow tapering of central neuromodulators is necessary to avoid discontinuation effects.